RT info:eu-repo/semantics/article
T1 Stability study of isoniazid and rifampicin oral solutions using hydroxypropyl-B-cyclodextrin to treat tuberculosis in paediatrics
A1 Echezarreta López, María Magdalena
A1 Santoveña Estévez, Ana María
A1 Suárez González, Javier
A1 Cáceres Pérez, Amor R.
A1 Ruiz Noda, Zuleima
A1 Machado Rodríguez, Sara
A1 Soriano, Mabel
A1 Fariña, José B.
A2 Ingeniería Química y Tecnología Farmacéutica
A2 Grupo de investigación: Desarrollo galénico de medicamentos
Instituto de investigación: Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias
K1 first-line antituberculosis paediatric treatment
K1 dose combination
K1 isoniazid
K1 pyrazinamide
K1 rifampicin
AB (1)Background: First-lineantituberculosistreatmentinpaediatricsentailstheadministration of Isoniazid, Pyrazinamide, and Rifampicin. This study examines the possibility of developing a combined dose liquid formulation for oral use that would facilitate dose adjustment and adherence to treatment for younger children. (2) Methods: The active pharmaceutical ingredients stability under in vitro paediatric digestive pH conditions have been checked. The samples were studied as individual or fixed combined paediatric dosages to determine the pH of maximum stability. The use of hydroxypropyl-β-cyclodextrin to improve Rifampicin solubility and the use of ascorbic acid to increase the stability of the formulation have been studied. (3) Results: Maximum stability of combined doses was determined at pH 7.4, and maximum complexation at pH 8.0. Taking this into account, formulations presented the minimum dose of two active pharmaceutical ingredients dissolved. The addition of ascorbic acid at 0.1% w/v enables the detection of a higher remaining quantity of both drugs after three days of storage at 5 ◦C. (4) Conclusions: a formulation which combines the minimum paediatric dosages dissolved recommended by WHO for Isoniazid and Rifampicin has been developed. Future assays are needed to prolong the stability of the formulation with the aim of incorporating Pyrazinamide to the solution.
YR 2020
FD 2020
LK http://riull.ull.es/xmlui/handle/915/37312
UL http://riull.ull.es/xmlui/handle/915/37312
LA en
NO Financiado porProID2017010094. Desarrollo de nuevos medicamentos para el tratamiento de la tuberculosis pediátrica: formas farmacéuticas de administración oral. Convocatoria: 2017/1 PI.ACIISI.17.02.06.ISACAM. Instauración de un sistema para el aseguramiento de la calidad de medicamentos utilizados en el tratamiento del SIDA y enfermedades tropicales desatendidas Convocatoria: 2019/0028 INTERREG.18
DS Repositorio institucional de la Universidad de La Laguna
RD 06-ago-2024